Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Ocular Manifestations and Management of Graft-versus-Host-Disease - A Comprehensive Review.

Created on 12 Sep 2026

Authors

Sumana Chatterjee, Jaya Gupta, Shweta Agarwal, Jayanta Kuila, Vishal Jhanji, Namrata Sharma

Published in

Ophthalmic research. Pages 1. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

Ocular graft-versus-host disease (oGVHD) is a critical complication following allogeneic hematopoietic stem cell transplantation, characterised by a T cell-mediated immune response that results in inflammation and damage to various ocular structures.
While the ocular surface is primarily affected, oGVHD can also impact other eye components, leading to debilitating symptoms. The diagnosis of oGVHD poses significant challenges due to its relapsing and remitting nature, complicating effective treatment strategies. Prompt identification of ocular manifestations is essential, as early intervention can prevent vision-threatening complications and improve patient outcomes. As research continues to evolve, understanding the underlying mechanisms and exploring innovative therapeutic options will be crucial in managing this complex condition effectively.
This review highlights the importance of heightened awareness among healthcare providers regarding the ocular signs of GVHD, advocating for timely diagnosis and personalised treatment approaches.

PMID:
42726679
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement